Calcium leak through ryanodine receptor is involved in neuronal death induced by mutant huntingtin

Biochemical and Biophysical Research Communications

Volumn 429, Issue 1-2, 2012, Pages 18-23

  Suzuki, Mari ^a,b   Nagai, Yoshitaka ^b   Wada, Keiji ^b   Koike, Tatsuro ^a,c  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c HOSEI UNIVERSITY   (Japan)

Author keywords

Calcium; Dantrolene; Neurodegeneration; Polyglutamine; Ryanodine receptor

Indexed keywords

CALCIUM; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; HUNTINGTIN; RYANODINE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MOUSE; NERVE CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; MICE; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACROLIMUS BINDING PROTEIN 1A;

MUS;

EID: 84870394065     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.10.107     Document Type: Article

References (33)

1. Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 2009, 110:1737-1765.
2. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
3. Lunkes A., Lindenberg K.S., Ben-Haiem L., Weber C., Devys D., Landwehrmeyer G.B., Mandel J.L., Trottier Y. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cells 2002, 10:259-269.
4. Nagai Y., Popiel H.A. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis. Curr. Pharm. Des. 2008, 14:3267-3279.
5. Bezprozvanny I., Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 2004, 322:1310-1317.
6. 2+ homeostasis in a peptide-delivery model of polyglutamine-induced neuronal death. J. Neurosci. Res. 2005, 80:549-561.
7. Mattson M.P., LaFerla F.M., Chan S.L., Leissring M.A., Shepel P.N., Geiger J.D. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2000, 23:222-229.
8. Tang T.S., Tu H., Chan E.Y., Maximov A., Wang Z., Wellington C.L., Hayden M.R., Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003, 39:227-239.
9. Chen X., Tang T.S., Tu H., Nelson O., Pook M., Hammer R., Nukina N., Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 2008, 28:12713-12724.
10. Liu J., Tang T.S., Tu H., Nelson O., Herndon E., Huynh D.P., Pulst S.M., Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J. Neurosci. 2009, 29:9148-9162.
11. Chen X., Wu J., Lvovskaya S., Herndon E., Supnet C., Bezprozvanny I. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol. Neurodegener. 2011, 6:81.
12. Lim D., Fedrizzi L., Tartari M., Zuccato C., Cattaneo E., Brini M., Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 2008, 283:5780-5789.
13. Bauer P.O., Hudec R., Ozaki S., Okuno M., Ebisui E., Mikoshiba K., Nukina N. Genetic ablation and chemical inhibition of IP3R1 reduce mutant huntingtin aggregation. Biochem. Biophys. Res. Commun. 2011, 416:13-17.
14. Oules B., Del Prete D., Greco B., Zhang X., Lauritzen I., Sevalle J., Moreno S., Paterlini-Brechot P., Trebak M., Checler F., Benfenati F., Chami M. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. J. Neurosci. 2012, 32:11820-11834.
15. Li F., Hayashi T., Jin G., Deguchi K., Nagotani S., Nagano I., Shoji M., Chan P.H., Abe K. The protective effect of dantrolene on ischemic neuronal cell death is associated with reduced expression of endoplasmic reticulum stress markers. Brain Res. 2005, 1048:59-68.
16. Muehlschlegel S., Sims J.R. Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit. Neurocrit. Care 2009, 10:103-115.
17. Wang G.H., Mitsui K., Kotliarova S., Yamashita A., Nagao Y., Tokuhiro S., Iwatsubo T., Kanazawa I., Nukina N. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport 1999, 10:2435-2438.
18. 2+ release channel (ryanodine receptor) function. FEBS Lett. 1997, 412:223-226.
19. Okadome T., Oeda E., Saitoh M., Ichijo H., Moses H.L., Miyazono K., Kawabata M. Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. J. Biol. Chem. 1996, 271:21687-21690.
20. Jiang M., Deng L., Chen G. High Ca(2+)-phosphate transfection efficiency enables single neuron gene analysis. Gene Ther. 2004, 11:1303-1311.
21. Liu X., Betzenhauser M.J., Reiken S., Meli A.C., Xie W., Chen B.X., Arancio O., Marks A.R. Role of leaky neuronal ryanodine receptors in stress- induced cognitive dysfunction. Cell 2012, 150:1055-1067.
22. 2+ release channels molecular mechanism and isoform selectivity. J. Biol. Chem. 2001, 276:13810-13816.
23. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., Hollingsworth Z.R., Collin F., Synek B., Holmans P.A., Young A.B., Wexler N.S., Delorenzi M., Kooperberg C., Augood S.J., Faull R.L., Olson J.M., Jones L., Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
24. Brillantes A.B., Ondrias K., Scott A., Kobrinsky E., Ondriasova E., Moschella M.C., Jayaraman T., Landers M., Ehrlich B.E., Marks A.R. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 1994, 77:513-523.
25. Lehnart S.E. Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak. Curr. Opin. Pharmacol. 2007, 7:225-232.
26. Giralt A., Saavedra A., Carreton O., Xifro X., Alberch J., Perez-Navarro E. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum. Mol. Genet. 2011, 20:4232-4247.
27. Perez-Severiano F., Escalante B., Vergara P., Rios C., Segovia J. Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Brain Res. 2002, 951:36-42.
28. Firdaus W.J., Wyttenbach A., Giuliano P., Kretz-Remy C., Currie R.W., Arrigo A.P. Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS J. 2006, 273:5428-5441.
29. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
30. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene. Eur. J. Neurosci. 2001, 14:1492-1504.
31. Gafni J., Ellerby L.M. Calpain activation in Huntington's disease. J. Neurosci. 2002, 22:4842-4849.
32. Nguyen H.N., Wang C., Perry D.C. Depletion of intracellular calcium stores is toxic to SH-SY5Y neuronal cells. Brain Res. 2002, 924:159-166.
33. 2+ store in the plasticity of central neurons. Trends Pharmacol. Sci. 2006, 27:78-84.